<p>/PRNewswire/ -- Salarius Pharmaceuticals, Inc.（&#34;Salarius&#34;或&#34;公司&#34;）（NASDAQ: SLRX）今天宣布了一项承销的公开发行定价，预计在扣除承销折扣、佣金及其他发行费用之前，筹集约 700 万美元的总收入。</p>
<p>此次发行包括 2,514,335 股普通股（&#34;普通股&#34;）和预先融资的认股权证，购买 2,152,331 股普通股，每种情况下均附带可购买最多 4,666,666 股普通股的 A 系列认股权证和可购买最多 4,666,666 股普通股的 B 系列认股权证。普通股及附带认股权证的联合公开发行价格为每股 1.50 美元，预先融资的认股权证及附带认股权证的联合公开发行价格为每个预先融资的认股权证 1.4999 美元。此次发行的认股权证为固定价格，不包含任何可变定价特征或替代行使条款。所有证券均由 Salarius 出售。</p>
<p>Ladenburg Thalmann &amp; Co. Inc.作为此次发行的唯一账簿管理人。</p>
<p>此次发行的交割预计将在 2025 年 11 月 12 日左右进行，具体取决于交割条件的满足，包括公司与 Decoy Therapeutics Inc.（&#34;Decoy&#34;）拟议的业务合并交易的完成。此外，Salarius 已授予承销商一个为期 45 天的选择权，以购买最多 699,999 股普通股和/或 699,999 个 A 系列认股权证和/或 699,999 个 B 系列认股权证，价格为各自的公开发行价格，扣除承销折扣和佣金。</p>
<p>Salarius 预计将利用此次发行的净收益（i）推进 Salarius 和 Decoy 的研究与开发项目的临床开发；（ii）偿还 Decoy 的某些未偿还的本票；以及（iii）用于其他一般企业用途，包括营运资金、研究与开发和资本支出。</p>
<p>每个预先融资的认股权证的行使价格为每个预先融资的认股权证 0.0001 美元，并且在该预先融资的认股权证完全行使之前可立即行使。每个 A 系列认股权证和 B 系列认股权证的行使价格为 1.50 美元。A 系列认股权证自发行之日起可行使五年。B 系列认股权证自发行之日起可行使一年。</p>
<p>上述证券是根据一份注册声明（表格 S-1，文件编号 333-284368）进行发行的，该声明根据 1933 年证券交易法第 8(a) 条的规定于 2025 年 11 月 10 日生效。</p>
<p>这些证券是通过与发行相关的招股说明书进行发行的，该招股说明书是注册声明的一部分。与此次发行相关的初步招股说明书已于 2025 年 10 月 21 日提交给证券交易委员会（&#34;SEC&#34;），并可在 SEC 的网站 www.sec.gov 上获取。与此次发行相关的最终招股说明书将提交给 SEC，并且也将在 SEC 的网站 www.sec.gov 上提供。在投资此次发行之前，您应完整阅读与此次发行相关的招股说明书以及 Salarius 向 SEC 提交的其他文件，这些文件在与此次发行相关的招股说明书中引用，提供有关 Salarius 和此次发行的更多信息。最终招股说明书的电子副本可在 SEC 的网站 http://www.sec.gov 上获取，或通过联系 Ladenburg Thalmann &amp; Co. Inc.，招股说明书部门，640 Fifth Avenue, 4th Floor, New York, New York 10019，或通过电子邮件联系 prospectus@ladenburg.com。</p>
<p>本新闻稿不构成出售要约或购买要约的征求，也不会在任何法律要求注册或资格之前在任何管辖区内销售这些证券。</p>
<p><strong>关于 Salarius Pharmaceuticals, Inc.</strong></p>
<p>Salarius Pharmaceuticals 是一家临床阶段的生物制药公司，拥有两种针对需要新治疗选择的癌症患者的药物候选者。Salarius 的产品组合包括 seclidemstat，该公司主要候选药物，正在 MD Anderson 癌症中心进行的由研究者发起的 1/2 期临床研究中，作为对 MDS 和慢性髓性单核细胞白血病（CMML）患者的潜在治疗。SP-3164 是该公司的 IND 阶段第二资产，是一种口服小分子蛋白降解剂。Salarius 之前获得了来自国家儿童癌症基金会的 seclidemstat 治疗尤文肉瘤的财政支持，并获得了来自德克萨斯州癌症预防与研究所（CPRIT）的产品开发奖。</p>
<p><strong>关于 Decoy Therapeutics, Inc.</strong></p>
<p>Decoy Therapeutics 是一家处于临床前阶段的生物技术公司，利用机器学习和人工智能工具，以及高速合成技术，快速设计、工程和制造针对严重未满足医疗需求的肽结合药物候选者。该公司的初步管道专注于呼吸道病毒和胃肠癌。Decoy 吸引了来自机构投资者的融资，以及来自马萨诸塞州生命科学种子基金、Google AI 初创企业计划和 NVIDIA Inception 计划等多个来源的显著非稀释资本。该公司还获得了由生物医学高级研究和开发局（BARDA）通过 BLUE KNIGHT™提供的 QuickFire Challenge 奖资助，这是强生创新–JLABS 与 BARDA 在战略准备和响应管理局内的合作。</p>
<p><strong>安全港声明</strong></p>
<p>本新闻稿包含 1995 年美国私人证券诉讼改革法案所定义的前瞻性声明。本新闻稿中不是历史事实的声明均为前瞻性声明。诸如 “可能”、“将”、“应该”、“期望”、“计划”、“预期”、“能够”、“打算”、“目标”、“项目”、“估计”、“相信”、“预测”、“潜在” 或 “继续” 以及这些术语的否定形式或其他类似表达，旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。本新闻稿中的前瞻性声明包括有关融资和 Decoy 合并及其预期时间的声明；与发行和 Decoy 合并相关的成交条件的满足，发行和 Decoy 合并的预期成交日期，以及发行的收益金额和预期用途。</p>
<p>公司可能无法实际实现前瞻性声明中披露的计划、意图或期望，因此您不应对前瞻性声明过于依赖。这些前瞻性声明涉及风险和不确定性，可能导致公司实际结果与前瞻性声明中描述或暗示的结果存在重大差异。对于 Salarius 而言，这包括满足发行和 Decoy 合并的惯例成交条件、获得所需股票交易所或其他监管批准的延迟、Salarius 和 Decoy 各自完成合并的能力；合并公司未能实现预期协同效应的风险；Salarius 和合并公司未能获得足够融资以执行其商业计划的风险；与 Decoy 的产品和开发计划相关的风险，包括任何 IND 申请过程中的意外问题以及 IMP3ACT™平台的潜力；政治不确定性、股价波动以及与金融市场、医疗界和全球经济相关的不确定性，以及一般商业和经济条件不稳定的影响，包括通货膨胀、利率和劳动力市场的变化。可能导致 Salarius 实际结果与本新闻稿中前瞻性声明所表达或暗示的结果存在重大差异的其他因素在向 SEC 提交的初步招股说明书中的 “风险因素” 标题下进行了描述，以及在 Salarius 截至 2024 年 12 月 31 日的年度报告（Form 10-K）中，以及 Salarius 向 SEC 的其他提交文件中，以及其未来向 SEC 提交的报告中可获得，网址为 www.sec.gov。本新闻稿中包含的前瞻性声明截至本日期作出，Salarius 不承担更新该信息的义务，无论是由于新信息、未来事件还是其他原因，除非适用法律要求。</p>
<p>来源：Salarius Pharmaceuticals, Inc.</p>

SLRX

<p>Salarius Pharmaceuticals, Inc. 宣布了一项 700 万美元的承销公开发行定价，包含 2,514,335 股普通股和 2,152,331 股的预先融资认股权证，以及 A 系列和 B 系列认股权证。发行价格定为每股 1.50 美元和每个预先融资认股权证 1.4999 美元。所得款项将用于临床开发、偿还 Decoy 的本票以及一般公司用途。该发行预计将在 2025 年 11 月 12 日左右完成，具体取决于某些条件</p>

<p>, /PRNewswire/ -- Salarius Pharmaceuticals, Inc. (&#34;Salarius&#34; or the &#34;Company&#34;) (NASDAQ: SLRX) today announced the pricing of an underwritten public offering for gross proceeds of approximately $7 million before deducting underwriting discounts and commissions and other offering expenses.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Salarius Pharmaceuticals, Inc.（&#34;Salarius&#34;或&#34;公司&#34;）（NASDAQ: SLRX）今天宣布了一项承销的公开发行定价，预计在扣除承销折扣、佣金及其他发行费用之前，筹集约 700 万美元的总收入。</p>
</div><p>The offering is comprised of 2,514,335 shares of its common stock (&#34;Common Stock&#34;) and pre-funded warrants to purchase 2,152,331 shares of Common Stock, in each case with accompanying Series A Warrants to purchase up to an aggregate of 4,666,666 shares of Common Stock and Series B Warrants to purchase up to an aggregate of 4,666,666 shares of Common Stock. The combined public offering price per share of Common Stock and accompanying warrants is$1.50per share and accompanying warrants, and the combined public offering price per pre-funded warrant and accompanying warrants is$1.4999per pre-funded warrant and accompanying warrants. The warrants issued in this offering are fixed priced and do not contain any variable pricing features or alternative exercise provisions. All of the securities are being sold by Salarius.</p>
<div class="lb-trans"><p>此次发行包括 2,514,335 股普通股（&#34;普通股&#34;）和预先融资的认股权证，购买 2,152,331 股普通股，每种情况下均附带可购买最多 4,666,666 股普通股的 A 系列认股权证和可购买最多 4,666,666 股普通股的 B 系列认股权证。普通股及附带认股权证的联合公开发行价格为每股 1.50 美元，预先融资的认股权证及附带认股权证的联合公开发行价格为每个预先融资的认股权证 1.4999 美元。此次发行的认股权证为固定价格，不包含任何可变定价特征或替代行使条款。所有证券均由 Salarius 出售。</p>
</div><p>Ladenburg Thalmann &amp; Co. Inc.is acting as sole book-running manager in connection with the offering.</p>
<div class="lb-trans"><p>Ladenburg Thalmann &amp; Co. Inc.作为此次发行的唯一账簿管理人。</p>
</div><p>The closing of the offering is expected to occur on or about November 12, 2025, subject to the satisfaction of closing conditions, including consummation of the Company's proposed business combination transaction with Decoy Therapeutics Inc. (&#34;Decoy&#34;). In addition, Salarius has granted the underwriter an option for a period of 45 days to purchase up to an additional 699,999 shares of Common Stock, and/or 699,999 Series A Warrants, and/or 699,999 Series B Warrants at their respective public offering prices, less underwriting discounts and commissions.</p>
<div class="lb-trans"><p>此次发行的交割预计将在 2025 年 11 月 12 日左右进行，具体取决于交割条件的满足，包括公司与 Decoy Therapeutics Inc.（&#34;Decoy&#34;）拟议的业务合并交易的完成。此外，Salarius 已授予承销商一个为期 45 天的选择权，以购买最多 699,999 股普通股和/或 699,999 个 A 系列认股权证和/或 699,999 个 B 系列认股权证，价格为各自的公开发行价格，扣除承销折扣和佣金。</p>
</div><p>Salarius expects to use the net proceeds from the offering (i) to advance the clinical development of Salarius' and Decoy's research and development programs; (ii) to pay off certain of Decoy's outstanding promissory notes as required thereby; and (iii) for other general corporate purposes, including working capital, research and development, and capital expenditures.</p>
<div class="lb-trans"><p>Salarius 预计将利用此次发行的净收益（i）推进 Salarius 和 Decoy 的研究与开发项目的临床开发；（ii）偿还 Decoy 的某些未偿还的本票；以及（iii）用于其他一般企业用途，包括营运资金、研究与开发和资本支出。</p>
</div><p>Each pre-funded warrant has an exercise price of $0.0001 per pre-funded warrant, and is immediately exercisable until such pre-funded warrant is exercised in full. Each of the Series A Warrants and Series B Warrants has an exercise price of $1.50. The Series A Warrants will be exercisable for a period of five years from the date of issuance. The Series B Warrants will be exercisable for a period of one year from the date of issuance.</p>
<div class="lb-trans"><p>每个预先融资的认股权证的行使价格为每个预先融资的认股权证 0.0001 美元，并且在该预先融资的认股权证完全行使之前可立即行使。每个 A 系列认股权证和 B 系列认股权证的行使价格为 1.50 美元。A 系列认股权证自发行之日起可行使五年。B 系列认股权证自发行之日起可行使一年。</p>
</div><p>The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333- 284368) that became effective in accordance with Section 8(a) of the Securities and Exchange Act of 1933, as amended, onNovember 10, 2025.</p>
<div class="lb-trans"><p>上述证券是根据一份注册声明（表格 S-1，文件编号 333-284368）进行发行的，该声明根据 1933 年证券交易法第 8(a) 条的规定于 2025 年 11 月 10 日生效。</p>
</div><p>The securities are being offered by means of a prospectus relating to the offering that form a part of the registration statement. A preliminary prospectus relating to the offering was filed with theSecurities and Exchange Commission (the &#34;SEC&#34;) onOctober 21, 2025,and is available on the SEC's website atwww.sec.gov. The final prospectus relating to and describing the terms of the offering will be filed with theSECand also will be available on the SEC's website atwww.sec.gov. Before investing in the offering, you should read prospectus relating to the offering in their entirety as well as the other documents that Salarius has filed with theSECthat are incorporated by reference in the prospectus relating to the offering, which provide more information about Salarius and the offering. Electronic copies of the final prospectus may be obtained, when available, on the SEC's website at http://www.sec.govor by contactingLadenburg Thalmann &amp; Co. Inc., Prospectus Department,640 Fifth Avenue, 4th Floor,New York, New York10019 or by email atprospectus@ladenburg.com.</p>
<div class="lb-trans"><p>这些证券是通过与发行相关的招股说明书进行发行的，该招股说明书是注册声明的一部分。与此次发行相关的初步招股说明书已于 2025 年 10 月 21 日提交给证券交易委员会（&#34;SEC&#34;），并可在 SEC 的网站 www.sec.gov 上获取。与此次发行相关的最终招股说明书将提交给 SEC，并且也将在 SEC 的网站 www.sec.gov 上提供。在投资此次发行之前，您应完整阅读与此次发行相关的招股说明书以及 Salarius 向 SEC 提交的其他文件，这些文件在与此次发行相关的招股说明书中引用，提供有关 Salarius 和此次发行的更多信息。最终招股说明书的电子副本可在 SEC 的网站 http://www.sec.gov 上获取，或通过联系 Ladenburg Thalmann &amp; Co. Inc.，招股说明书部门，640 Fifth Avenue, 4th Floor, New York, New York 10019，或通过电子邮件联系 prospectus@ladenburg.com。</p>
</div><p>This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售要约或购买要约的征求，也不会在任何法律要求注册或资格之前在任何管辖区内销售这些证券。</p>
</div><p><strong>About Salarius Pharmaceuticals, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Salarius Pharmaceuticals, Inc.</strong></p>
</div><p>Salarius Pharmaceuticalsis a clinical-stage biopharmaceutical company with two drug candidates for patients with cancer in need of new treatment options. Salarius' product portfolio includes seclidemstat, the company's lead candidate, which is being studied in an investigator-initiated Phase 1/2 clinical study in hematologic cancers underway atMD Anderson Cancer Centeras a potential treatment for MDS) and chronic myelomonocytic leukemia (CMML) in patients with limited treatment options. SP-3164, the company's IND-stage second asset, is an oral small molecule protein degrader. Salarius previously received financial support for seclidemstat for the treatment of Ewing sarcoma from theNational Pediatric Cancer Foundationand was a recipient of a Product Development Award from theCancer Prevention and Research Institute of Texas(CPRIT).</p>
<div class="lb-trans"><p>Salarius Pharmaceuticals 是一家临床阶段的生物制药公司，拥有两种针对需要新治疗选择的癌症患者的药物候选者。Salarius 的产品组合包括 seclidemstat，该公司主要候选药物，正在 MD Anderson 癌症中心进行的由研究者发起的 1/2 期临床研究中，作为对 MDS 和慢性髓性单核细胞白血病（CMML）患者的潜在治疗。SP-3164 是该公司的 IND 阶段第二资产，是一种口服小分子蛋白降解剂。Salarius 之前获得了来自国家儿童癌症基金会的 seclidemstat 治疗尤文肉瘤的财政支持，并获得了来自德克萨斯州癌症预防与研究所（CPRIT）的产品开发奖。</p>
</div><p><strong>About Decoy Therapeutics, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Decoy Therapeutics, Inc.</strong></p>
</div><p>Decoy Therapeutics is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The company's initial pipeline is focused on respiratory viruses and GI cancers. Decoy has attracted financing from institutional investors as well as significant non-dilutive capital from theMassachusetts Life Sciences Seed Fund, theGoogleAI startup program and the NVIDIA Inception program among other sources. The company has also received QuickFire Challenge award funding provided by theBiomedical Advanced Research and Development Authority(BARDA) through BLUE KNIGHT™, a collaboration betweenJohnson &amp; Johnson Innovation– JLABS and BARDA within the Administration for Strategic Preparedness and Response.</p>
<div class="lb-trans"><p>Decoy Therapeutics 是一家处于临床前阶段的生物技术公司，利用机器学习和人工智能工具，以及高速合成技术，快速设计、工程和制造针对严重未满足医疗需求的肽结合药物候选者。该公司的初步管道专注于呼吸道病毒和胃肠癌。Decoy 吸引了来自机构投资者的融资，以及来自马萨诸塞州生命科学种子基金、Google AI 初创企业计划和 NVIDIA Inception 计划等多个来源的显著非稀释资本。该公司还获得了由生物医学高级研究和开发局（BARDA）通过 BLUE KNIGHT™提供的 QuickFire Challenge 奖资助，这是强生创新–JLABS 与 BARDA 在战略准备和响应管理局内的合作。</p>
</div><p><strong>Safe Harbor Statement</strong></p>
<div class="lb-trans"><p><strong>安全港声明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as &#34;may,&#34; &#34;will,&#34; &#34;should,&#34; &#34;expect,&#34; &#34;plan,&#34; &#34;anticipate,&#34; &#34;could,&#34; &#34;intend,&#34; &#34;target,&#34; &#34;project,&#34; &#34;estimate,&#34; &#34;believe,&#34; &#34;predict,&#34; &#34;potential&#34; or &#34;continue&#34; or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the financing and the Decoy merger and the expected timing thereof; the satisfaction of closing conditions related to the offering and the Decoy merger, the expected closing date of the offering and the Decoy merger and the amount and expected use of proceeds from the offering.</p>
<div class="lb-trans"><p>本新闻稿包含 1995 年美国私人证券诉讼改革法案所定义的前瞻性声明。本新闻稿中不是历史事实的声明均为前瞻性声明。诸如 “可能”、“将”、“应该”、“期望”、“计划”、“预期”、“能够”、“打算”、“目标”、“项目”、“估计”、“相信”、“预测”、“潜在” 或 “继续” 以及这些术语的否定形式或其他类似表达，旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。本新闻稿中的前瞻性声明包括有关融资和 Decoy 合并及其预期时间的声明；与发行和 Decoy 合并相关的成交条件的满足，发行和 Decoy 合并的预期成交日期，以及发行的收益金额和预期用途。</p>
</div><p>The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. For Salarius, this includes satisfaction of the customary closing conditions of the offering and the Decoy merger, delays in obtaining required stock exchange or other regulatory approvals,the ability of each of Salarius and Decoy to consummate the merger; risks that the combined company will not achieve the synergies expected from the proposed merger; risks that Salarius and the combined company will not obtain sufficient financing to execute on their business plans; risks related to Decoy's products and development plans, including unanticipated issues with any IND application process and the potential of the IMP3ACT™ platform; political uncertainties, stock price volatility and uncertainties relating to the financial markets, the medical community and the global economy, and the impact of instability in general business and economic conditions, including changes in inflation, interest rates and the labor market. Other factors that may cause Salarius' actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading &#34;Risk Factors&#34; in the preliminary prospectus filed with the SEC and in Salarius' Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC, and in Salarius' other filings with the SEC, and in its future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this press release are made as of this date, and Salarius undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.</p>
<div class="lb-trans"><p>公司可能无法实际实现前瞻性声明中披露的计划、意图或期望，因此您不应对前瞻性声明过于依赖。这些前瞻性声明涉及风险和不确定性，可能导致公司实际结果与前瞻性声明中描述或暗示的结果存在重大差异。对于 Salarius 而言，这包括满足发行和 Decoy 合并的惯例成交条件、获得所需股票交易所或其他监管批准的延迟、Salarius 和 Decoy 各自完成合并的能力；合并公司未能实现预期协同效应的风险；Salarius 和合并公司未能获得足够融资以执行其商业计划的风险；与 Decoy 的产品和开发计划相关的风险，包括任何 IND 申请过程中的意外问题以及 IMP3ACT™平台的潜力；政治不确定性、股价波动以及与金融市场、医疗界和全球经济相关的不确定性，以及一般商业和经济条件不稳定的影响，包括通货膨胀、利率和劳动力市场的变化。可能导致 Salarius 实际结果与本新闻稿中前瞻性声明所表达或暗示的结果存在重大差异的其他因素在向 SEC 提交的初步招股说明书中的 “风险因素” 标题下进行了描述，以及在 Salarius 截至 2024 年 12 月 31 日的年度报告（Form 10-K）中，以及 Salarius 向 SEC 的其他提交文件中，以及其未来向 SEC 提交的报告中可获得，网址为 www.sec.gov。本新闻稿中包含的前瞻性声明截至本日期作出，Salarius 不承担更新该信息的义务，无论是由于新信息、未来事件还是其他原因，除非适用法律要求。</p>
</div><p>SOURCE Salarius Pharmaceuticals, Inc.</p>
<div class="lb-trans"><p>来源：Salarius Pharmaceuticals, Inc.</p>
</div>

Salarius Pharmaceuticals 宣布 700 万美元包销公开发行的定价 | SLRX 股票新闻